"There are also people who avoid the doctor's office, not because they're afraid of needles, but because they can't afford it," says growth stock specialist Marc Lichtenfeld.

The contributing editor to Investment U explains, "However, times are changing. The new health care bill will enable millions more people to get their various conditions checked out. As a result, the diagnostics industry should boom.

This post is part of a 12-article feature on the best bets for investing in China. To see all the other recommendations in this special report, click here.

"Mindray Medical International (NYSE: MR), based in Shenzhen, China and run by entrepreneurs, is a great defensive growth play," says Ian Wyatt in Top Stock Insights.Here's his review.

"This maker of medical devices boasts a strong brand and sales network with heavy investments in R&D and a smorgasbord of products.

This post is part of a special report, Global advisors look to China.

"Bull markets are born in the pits of despair; from current low stock prices and low PE valuations, the gains over the coming 5 to 10 years could be truly spectacular," says Tom Bishop.

In his BI Research, the small cap growth specialist looks at two stocks that are based in China and set to benefit from China's stimulus program: energy efficiency play, SmartHeat (NASDAQ: HEAT) and medical diagnostics firm, Mindray Medical (NYSE: MR).

In The Oberweis Report, growth expert Jim Oberweis. Jr. sees upside for risk-oriented investors in two diagnostics firms: Myriad Genetics (NASDAQ: MYGN) and Thoratec (NASDAQ: THOR).

"Myriad develops molecular diagnostic products focused in the area of predictive caner diagnostics. It currently sells five genetic tests (and just recently announced the launch of a 6th test in December) focused on cancer and women's health.

"The bulk of their revenues currently come from their BRACAnalysis test for breast cancer. This test is the only one of its kind available to detect a faulty version of BRAC genes in women, which has been linked to significantly increased chances of developing breast and ovarian cancers.